List of articles with "Obesity Treatment"

Viking Launches VK3019 Trial

Viking Launches VK3019 Trial

United States San Diego Viking Therapeutics Obesity Treatment VK3019
FDA Clearance for ASC35

FDA Clearance for ASC35

United States Hong Kong Ascletis Obesity Treatment ASC35
MyPhenome: Personalized Weight Loss

MyPhenome: Personalized Weight Loss

USA Menlo Park Obesity Treatment Phenomix Sciences MyPhenome
Innovent's Pipeline Updates

Innovent's Pipeline Updates

China Suzhou Innovent Biologics Obesity Treatment metabolic pipeline
Ascletis at ADA 2026

Ascletis at ADA 2026

USA New Orleans Obesity Treatment ASC30 Ascletis Pharma
Retatrutide's Impact

Retatrutide's Impact

United States Indianapolis Eli Lilly Obesity Treatment retatrutide
Obesity Therapy in Shibuya

Obesity Therapy in Shibuya

Japan Obesity Treatment GLP-1 Medication Shibuya Shibuya Sakura Stage
Novo Nordisk and Hinode

Novo Nordisk and Hinode

Japan Novo Nordisk Obesity Treatment Hinode Hinode Town
Mayo Clinic's MyPhenome Test Insights

Mayo Clinic's MyPhenome Test Insights

USA Menlo Park Obesity Treatment Phenomix Sciences MyPhenome Test
Neurocrine Study Launch

Neurocrine Study Launch

USA San Diego Neurocrine Obesity Treatment NBIP-'2118
Viking Therapeutics Q1 Update

Viking Therapeutics Q1 Update

United States San Diego Viking Therapeutics Obesity Treatment VK2735
Wegovy® vs Orforglipron

Wegovy® vs Orforglipron

USA San Diego Wegovy Obesity Treatment Orforglipron
GLP-1s: Progress in Obesity

GLP-1s: Progress in Obesity

USA Menlo Park GLP-1 Obesity Treatment Phenomix Sciences
Wegovy® HD Launch

Wegovy® HD Launch

United States Novo Nordisk Plainsboro Obesity Treatment Wegovy HD
ASC39 and Obesity

ASC39 and Obesity

USA Hong Kong Obesity Treatment Ascletis Pharma ASC39
Ascletis ASC30 Phase II Results

Ascletis ASC30 Phase II Results

USA California Ascletis Obesity Treatment ASC30
WHO and Lilly Team Up

WHO and Lilly Team Up

Switzerland Geneva Eli Lilly Obesity Treatment WHO Foundation
GLP-1 Users and Side Effects

GLP-1 Users and Side Effects

USA Menlo Park GLP-1 Obesity Treatment Phenomix Sciences
Innovative Obesity Treatment Trial

Innovative Obesity Treatment Trial

United States San Diego Obesity Treatment BL-001 Bloom Science
Knownwell's Success in Obesity

Knownwell's Success in Obesity

USA Boston Obesity Treatment Knownwell Clinical Report
Gutte's Obesity Seminar

Gutte's Obesity Seminar

Japan Nutrition Obesity Treatment Chiyoda Gutte
MetaVia Patent for DA-1726

MetaVia Patent for DA-1726

United States Cambridge MetaVia Obesity Treatment DA-1726
ASC37: Obesity Treatment

ASC37: Obesity Treatment

China Hong Kong Ascletis Obesity Treatment ASC37
HealthDyne Obesity Solutions

HealthDyne Obesity Solutions

USA Lakeland Eli Lilly Obesity Treatment HealthDyne
VK2735 Clinical Trial Enrollment Completed

VK2735 Clinical Trial Enrollment Completed

USA San Diego Viking Therapeutics Obesity Treatment VK2735
MetaVia's DA-1726 Trial Results

MetaVia's DA-1726 Trial Results

United States Cambridge MetaVia Obesity Treatment DA-1726
CagriSema FDA Submission

CagriSema FDA Submission

USA Novo Nordisk Plainsboro Obesity Treatment CagriSema
Orforglipron Weight Loss

Orforglipron Weight Loss

United States Indianapolis Eli Lilly Obesity Treatment Orforglipron
Viking VK2735 Trial Completed

Viking VK2735 Trial Completed

United States San Diego Viking Therapeutics Obesity Treatment VK2735
Palatin Q1 2026 Update

Palatin Q1 2026 Update

USA Palatin Technologies Princeton Obesity Treatment MC4R Agonists
CureGene's CG-0416

CureGene's CG-0416

China Shanghai CureGene Obesity Treatment CG-0416
Nitinotes EndoZip Approval

Nitinotes EndoZip Approval

Israel Caesarea Obesity Treatment EndoZip Nitinotes
MetaVia Q3 2025 Update

MetaVia Q3 2025 Update

United States Cambridge Obesity Treatment MetaVia Inc DA-1726
Promise of Eloralintide

Promise of Eloralintide

USA Indianapolis Eli Lilly Obesity Treatment eloralintide
VK2735 Trial Launch

VK2735 Trial Launch

USA San Diego Viking Therapeutics Obesity Treatment VK2735
Innovative Mechanism for Obesity

Innovative Mechanism for Obesity

USA Endevica Bio Northbrook, Illinois Obesity Treatment 710GO
Rona's Novel siRNA for Obesity

Rona's Novel siRNA for Obesity

USA Santa Barbara Obesity Treatment Rona Therapeutics RN3161
Lilly's Obesity Breakthrough

Lilly's Obesity Breakthrough

United States Indianapolis Eli Lilly Obesity Treatment Orforglipron
VK2735 Weight Loss Success

VK2735 Weight Loss Success

United States San Diego Viking Therapeutics Obesity Treatment VK2735
Radella's MD-18 Weight Loss

Radella's MD-18 Weight Loss

United States New York Obesity Treatment Radella Pharmaceuticals MD-18
Non-Surgical Obesity Treatment

Non-Surgical Obesity Treatment

Japan Tokyo Obesity Treatment Gastric Botox Kodai Takahashi
Ascletis ASC30 Study

Ascletis ASC30 Study

United States Hong Kong Ascletis Obesity Treatment ASC30
Viking Q2 2025 Update

Viking Q2 2025 Update

USA San Diego Viking Therapeutics Obesity Treatment VK2735
MC4R Agonist Advances

MC4R Agonist Advances

United States Boston Obesity Treatment MC4R agonist Superluminal
Healthcare Forum

Healthcare Forum

Japan Tokyo Healthcare Innovation Eli Lilly Obesity Treatment
MetaVia Phase 1 Trial

MetaVia Phase 1 Trial

United States Cambridge MetaVia Obesity Treatment DA-1726
RESET® Device CE Mark Success

RESET® Device CE Mark Success

USA Boston Obesity Treatment Morphic Medical RESET®
Low GLP-1 Drug Persistence

Low GLP-1 Drug Persistence

USA GLP-1 Eagan Obesity Treatment Prime Therapeutics
FDA Approval for EndoZip™

FDA Approval for EndoZip™

USA Caesarea Obesity Treatment Nitinotes EndoZip™
Obesity Treatment Update

Obesity Treatment Update

United States Obesity Treatment Belmont Supercede Therapeutics SPCD-4-79

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.